MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Submission of Matters to a Vote of Security Holders

MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.

At the Special Meeting of Stockholders of MabVax Therapeutics Holdings, Inc. (the “Company”) that was re-convened on October 6, 2017, a total of 6,502,910 shares, or 52.19%, of the Company's stock entitled to vote at the Special Meeting, including Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, and Series J Convertible Preferred Stock voting on an as-converted basis, subject to certain voting limitations set forth in the respective governing Certificates of Designation, were represented in person or by proxy.

Set forth below is a brief description of the remaining matter voted upon at the re-convened Special Meeting (the “Reverse Split Proposal”) and the voting results.

1) To grant the Board of Directors the authority, in its sole direction, in determining a higher stock price is required to continue to meet the continued listing qualifications for the NASDAQ Stock Exchange, to approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our issued and outstanding common stock by a ratio of not less than one-for-two and not more than one-for-twenty at any time prior to September 28, 2018, with the exact ratio to be set at a whole number within this range as determined by the Board of Directors.

The proposal was approved.

The Special Meeting was initially convened on September 28, 2017 to approve six proposals and was adjourned to October 2, 2017 to achieve a quorum on all proposals. On October 2, 2017, a quorum was achieved and five of the six proposals were voted on and approved as disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 3, 2017. The meeting was adjourned to October 6, 2017 to solicit additional votes for the Reverse Split Proposal.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.

MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Ex 99-1   Exhibit 99.1 MabVax Stockholders Approve Remaining Proposal at Special Meeting of Stockholders   Recent Capital Raises Enable Continued Advancement of Clinical Programs to Key Data Milestones     San Diego,…To view the full exhibit click here